- Home
- ATHA vs TRIB Comparison
ATHA vs TRIB Comparison
Compare ATHA & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- TRIB
- Stock Information
- Founded
- ATHA 2011
- TRIB 1992
- Country
- ATHA United States
- TRIB Ireland
- Employees
- ATHA N/A
- TRIB N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATHA Health Care
- TRIB Health Care
- Exchange
- ATHA Nasdaq
- TRIB Nasdaq
- Market Cap
- ATHA 21.0M
- TRIB 25.5M
- IPO Year
- ATHA 2020
- TRIB N/A
- Fundamental
- Price
- ATHA $0.31
- TRIB $0.70
- Analyst Decision
- ATHA Buy
- TRIB
- Analyst Count
- ATHA 4
- TRIB 0
- Target Price
- ATHA $11.25
- TRIB N/A
- AVG Volume (30 Days)
- ATHA 174.6K
- TRIB 120.1K
- Earning Date
- ATHA 02-27-2025
- TRIB 04-03-2025
- Dividend Yield
- ATHA N/A
- TRIB N/A
- EPS Growth
- ATHA N/A
- TRIB N/A
- EPS
- ATHA N/A
- TRIB N/A
- Revenue
- ATHA N/A
- TRIB $59,126,000.00
- Revenue This Year
- ATHA N/A
- TRIB $11.63
- Revenue Next Year
- ATHA N/A
- TRIB $10.13
- P/E Ratio
- ATHA N/A
- TRIB N/A
- Revenue Growth
- ATHA N/A
- TRIB N/A
- 52 Week Low
- ATHA $0.30
- TRIB $0.63
- 52 Week High
- ATHA $3.67
- TRIB $3.55
- Technical
- Relative Strength Index (RSI)
- ATHA 25.07
- TRIB 40.83
- Support Level
- ATHA $0.34
- TRIB $0.63
- Resistance Level
- ATHA $0.40
- TRIB $0.77
- Average True Range (ATR)
- ATHA 0.04
- TRIB 0.06
- MACD
- ATHA -0.01
- TRIB -0.00
- Stochastic Oscillator
- ATHA 6.41
- TRIB 28.70
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.